Paul Andrew Moore sold $505k of ZYME
Chief Scientific Officer at Zymeworks Inc.. 20,110 shares at an average of $25.10, traded Jan 5, 2026, filed Jan 5, 2026.
Score components
- +15RoleOfficer
- +18Trade size$505k at market
- +10Share of holdings soldSold 50% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-003095, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | MOption exercise Common Stock | +17,168 | $0.00 | $0 | 40,501 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock | -9,289 | $25.10 | $233k | 31,212 | Jan 5, 2026 |
| Jan 5, 2026 | MOption exercise Common Stock | +20,000 | $0.00 | $0 | 51,212 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock | -10,821 | $25.10 | $272k | 40,391 | Jan 5, 2026 |
| Jan 5, 2026 | MOption exercise Restricted Stock Unitderivative | -17,168 | $0.00 | $0 | 0 | Jan 5, 2026 |
| Jan 5, 2026 | MOption exercise Restricted Stock Unitderivative | -20,000 | $0.00 | $0 | 20,000 | Jan 5, 2026 |
Related signals
Other insiders at Zymeworks Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | ZYMEsell Zymeworks Inc. | Adam Schayowitz EVP, Head of R&D | $358k 13,832 shares | -37% | |
| 31Weak | Zymeworks Inc. | Mark Hollywood EVP & Chief Operating Officer | $139k 6,120 shares | -4% | |
| 51Moderate | Zymeworks Inc. | Kenneth Galbraith Chair & CEO | $690k 30,424 shares | -12% | |
| 32Weak | Zymeworks Inc. | Paul Andrew Moore Chief Scientific Officer | $217k 9,560 shares | -16% | |
| 37Weak | Zymeworks Inc. | Jeffrey T L Smith EVP & Chief Medical Officer | $211k 9,310 shares | -26% | |
| 60Notable | Zymeworks Inc. | Kenneth Galbraith Chair & CEO | $1.4M 54,343 shares | -30% | |
| 38Weak | Zymeworks Inc. | Jeffrey T L Smith EVP & Chief Medical Officer | $264k 10,538 shares | -36% | |
| 60Notable | Zymeworks Inc. | Kenneth Galbraith Chair & CEO | $1.3M 47,528 shares | -26% | |
| 43Moderate | ZYMEbuy Zymeworks Inc. | EcoR1 Capital, LLC director, owner | $636k 55,421 shares | +0% | |
| 48Moderate | ZYMEbuy Zymeworks Inc. | EcoR1 Capital, LLC director, owner | $1.5M 128,713 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.